{
    "2019-11-28": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis's $90 million Swiss factory to help solve cell therapy bottleneck",
                "features": {
                    "keywords": [
                        "Novartis",
                        "factory",
                        "cell therapy",
                        "bottleneck"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis cholesterol deal highlights mass-market opportunity",
                "features": {
                    "keywords": [
                        "Novartis",
                        "cholesterol",
                        "deal",
                        "mass-market",
                        "opportunity"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}